Nuvaira

About Nuvaira

Nuvaira is a healthcare startup that operates in the medical technology sector, specifically focusing on innovative therapies for Chronic Obstructive Pulmonary Disease (COPD). COPD is a common lung disease that affects over 16 million Americans and is responsible for $72 billion in annual healthcare expenses. Nuvaira's primary product is the dNerva® Lung Denervation System, a catheter-based system designed to treat overactive airways, which is a common issue in COPD patients.

The dNerva system works by disrupting nerve input to and from the lungs, reducing the clinical consequences of neural hyperactivity. This is a one-time, outpatient procedure that aims to reduce the frequency and severity of COPD exacerbations. The company's data shows that this treatment can lower the risk of severe exacerbation in COPD patients by 62% after two years.

Nuvaira's business model is based on the sales of the dNerva system to healthcare providers. The company operates in a market with a high demand due to the increasing number of COPD patients and the high costs associated with the disease. Despite the availability of prescribed medications, half of the patients on optimal medical therapy continue to experience exacerbations, indicating a need for more effective treatments like the dNerva system.